Secondary Malignant (Metastases)
Brain metastasis is the most common indication for stereotactic radiosurgery (SRS). SRS is a safe and effective treatment modality for patients with good performance status and limited number of brain metastases. In addition, SRS serves as an adjuvant therapy for resected brain lesions. Accumulating studies also support the use of hypofractionated stereotactic radiotherapy (HSRT), or Fractionated stereotactic radiotherapy (FSRT) delivering 27–35 Gy in 3–5 fractions for relatively large brain lesions and resection beds.
KeywordsBrain metastasis Stereotactic radiosurgery Hypofractionated stereotactic radiotherapy Whole-brain radiotherapy
- 4.Mulvenna P, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet Lond Engl. 2016;388:2004–14.CrossRefGoogle Scholar
- 19.Andrews DW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet Lond. Engl. 2004;363:1665–72.Google Scholar
- 23.Ammirati M, Kshettry VR, Lamki T, Wei L, Grecula JC. A prospective phase II trial of fractionated stereotactic intensity modulated radiotherapy with or without surgery in the treatment of patients with 1 to 3 newly diagnosed symptomatic brain metastases. Neurosurgery. 2014;74:586–94; discussion 594.CrossRefPubMedGoogle Scholar